University of California San Francisco
Give to UCSF
UCSF's Alan Ashworth, PhD, has received an award from a cancer nonprofit organization for his “significant contributions to research, advocacy, clinical care, education, awareness, or support of hereditary cancer.”
A new study led by UCSF has found that women with dense breasts may need only routine mammograms unless they are at high risk.
A team led by UCSF scientists has discovered a possible reason why angiogenesis inhibitors often work in the short term but usually become ineffective within months, one that could lead to a way to prevent cancer relapse.
A research team at UCSF has won a five-year award of $14.1 million from the Patient-Centered Outcomes Research Institute to investigate whether a personalized approach to breast cancer screening is as safe and effective as annual mammograms.
UCSF Chancellor and Professor Emeritus J. Michael Bishop, MD, Professor Emeritus Harold Varmus, MD, and Chancellor and Professor Emeritus Susan Desmond-Hellmann, MD, MPH, will be highlighted for their pioneering work on cancer in the Ken Burns-produced PBS documentary series “Cancer: The Emperor of All Maladies,” which airs March 30-April 1, 2015.
Alan Ashworth, one of the world's preeminent cancer scientists, recently began his new role as the director of the UCSF Helen Diller Family Comprehensive Cancer Center.
The UCSF community is deeply saddened to learn of the passing of Helen Diller, who was a longtime champion of UCSF, in particular through her family foundation’s support of the UCSF Helen Diller Family Comprehensive Cancer Center.
After more than 10 years of planning and construction, UCSF Medical Center at Mission Bay will open Feb. 1, 2015 on UCSF’s world-renowned biomedical research campus.
An international research collaboration led by UCSF researchers has identified a genetic variant common in Latina women that protects against breast cancer.
A newly discovered population of immune cells in tumors is associated with less severe cancer outcomes in humans, and may have therapeutic potential, according to a new UCSF study.
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UCSF.
New research partly led by UCSF-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated.
In an innovative clinical trial led by UCSF, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another decade, according to a review of the scientific literature by experts at UCSF and Harvard medical schools.